Press Releases Ypsomed Group

Burgdorf – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJEX™ syringe with the drug Teribone™ and assemble it with the YpsoMate prefilled autoinjector from Ypsomed. Teribone™ is a Teriparatide for the treatment of osteoporosis. The drug was developed by Asahi Kasei Pharma (AKP) and will be launched in Japan.

Teribone™ autoinjector
Teribone™ autoinjector

The pre-filled Teribone™ autoinjector is based on Ypsomed's YpsoMate platform and is designed for subcutaneous injection of liquid drugs. Terumo assembles the YpsoMate with its proprietary PLAJEX™ syringe for administration of the drug. AKP received market approval for Teribone™ in September 2019 and is launching the drug in Japan in December 2019.

Teribone™ is indicated for the treatment of patients living with Osteoporosis. Osteoporosis is a condition in which the bones become weaker and more fragile. According to the World Health Organisation (WHO), around 200 million people live with Osteoporosis worldwide. To date, Teribone™ has been available in a lyophilized vial formulation, and administration has taken place in the doctor's office. With the launch of Teribone™ in Ypsomed's pre-filled 2-step YpsoMate autoinjector, patients now have the opportunity to administer the drug themselves at home twice a week, if the treating physician recommends it.

Ypsomed and Terumo have worked closely together to enhance the value of Teribone™. With the combination of the YpsoMate autoinjector and PLAJEX™, we are able to provide a new treatment option to patients,

says Tetsuya Kumei, Division President of the Alliance Division, General Hospital Company of Terumo Corporation.

The Teribone™ autoinjector is already the second commercial market entry with Terumo. We see a growing need for easy-to-use injection devices for home use to increase quality of life, patient adherence and thus reduce healthcare costs,

comments Ulrike Bauer, Senior Vice President Ypsomed Delivery Systems.

Thomas Kutt
Head of Investor Relations
Ypsomed Holding AG

Go Back